Abstract:PurposeG Protein-Coupled Receptors (GPCRs) are a large family of therapeutically important proteins and as diverse X-ray structures become available it is increasingly possible to leverage structural information for rational drug design.We present herein approaches that use explicit water networks combined with energetic surveys of the binding site (GRID), providing an enhanced druggability and ligand design approach, with structural understanding of ligand binding, including a ‘magic’ methyl and binding site mutations, and a fast new approach to generate and score waters.MethodsThe GRID program was used to identify lipophilic and hydrogen bonding hotspots. Explicit full water networks were generated and scored for (pseudo)apo structures and ligand-protein complexes using a new approach, WaterFLAP (Molecular Discovery), together with WaterMap (Schrödinger) for (pseudo)apo structures. A scoring function (MetaScore) was developed using a fast computational protocol based on several short adiabatic biased MD simulations followed by multiple short well-tempered metadynamics runs.ResultsAnalysis of diverse ligands binding to the adenosine A2A receptor together with new structures for the δ/κ/μ opioid and CCR5 receptors confirmed the key role of lipophilic hotspots in driving ligand binding and thus design; the displacement of ‘unhappy’ waters generally found in these regions provides a key binding energy component. Complete explicit water networks could be robustly generated for protein-ligand complexes using a WaterFLAP based approach. They provide a structural understanding of structure-activity relationships such as a ‘magic methyl’ effect and with the metadynamics approach a useful estimation of the binding energy changes resulting from active site mutations.ConclusionsThe promise of full structure-based drug design (SBDD) for GPCRs is now possible using a combination of advanced experimental and computational data. The conformational thermostabilisation of StaR® proteins provide the ability to easily generate biophysical screening data (binding including fragments, kinetics) and to get crystal structures with both potent and weak ligands. Explicit water networks for apo and ligand-complex structures are a critical ‘third dimension’ for SBDD and are key for understanding ligand binding energies and kinetics. GRID lipophilic hotspots are found to be key drivers for binding. In this context ‘high end’ GPCR ligand design is now enabled.

Ligand binding at the protein–lipid interface: strategic considerations for drug design

Cellular Membranes and Lipid-Binding Domains As Attractive Targets for Drug Development.

Computational and theoretical approaches for studies of a lipid recognition protein on biological membranes

Druggable Lipid GPCRs: Past, Present, and Prospects

Intercellular Receptor-ligand Binding: Effect of Protein-membrane Interaction.

Computer Modeling for Interaction of Ligands and Receptors and Their Applications in Drug Design

New trends in computational structure prediction of ligand-protein complexes for receptor-based drug design

Nanoparticle Ligand Exchange and Its Effects at the Nanoparticle-Cell Membrane Interface

Discovery of lipid binding sites in a ligand-gated ion channel by integrating simulations and cryo-EM

Progress in ligand design for monolayer-protected nanoparticles for nanobio interfaces

Molecular Modeling-Guided Design of Phospholipid-Based Prodrugs

Ligandability at the membrane interface of GPx4 revealed through a reverse micelle fragment screening platform

Rational Design of Drugs Targeting G-Protein-Coupled Receptors: Ligand Search and Screening

Drugging Membrane Protein Interactions

High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks

How Ligands Illuminate GPCR Molecular Pharmacology

Rational Design of Drugs Targeting G-Protein-Coupled Receptors: A Structural Biology Perspective

Unravelling the interactions between small molecules and liposomal bilayers via molecular dynamics and thermodynamic modelling

Towards Structure-Based Protein Drug Design

Structure-based drug design: aiming for a perfect fit